Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ702MR)

This product GTTS-WQ702MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ702MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4371MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ239MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ13422MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ6313MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ7590MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA G-CSF
GTTS-WQ9797MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ10412MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ9017MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW